JPMorgan Chase & Co. Boosts TG Therapeutics (NASDAQ:TGTX) Price Target to $43.00

TG Therapeutics (NASDAQ:TGTX) had its price objective lifted by JPMorgan Chase & Co. from $30.00 to $43.00 in a research report released on Monday morning,Benzinga reports. The firm currently has an overweight rating on the biopharmaceutical company’s stock.

A number of other research firms have also recently commented on TGTX. HC Wainwright boosted their target price on shares of TG Therapeutics from $49.00 to $55.00 and gave the stock a “buy” rating in a research note on Tuesday, November 5th. The Goldman Sachs Group upped their price objective on shares of TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. B. Riley upped their price objective on shares of TG Therapeutics from $29.00 to $34.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. Finally, TD Cowen began coverage on shares of TG Therapeutics in a research note on Tuesday, October 29th. They set a “buy” rating and a $50.00 price objective for the company. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $40.67.

TG Therapeutics Trading Up 2.2 %

Shares of TG Therapeutics stock opened at $35.00 on Monday. The firm has a 50-day simple moving average of $26.19 and a two-hundred day simple moving average of $22.04. The company has a market cap of $5.45 billion, a P/E ratio of -349.97 and a beta of 2.19. TG Therapeutics has a fifty-two week low of $12.32 and a fifty-two week high of $36.84. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59.

TG Therapeutics (NASDAQ:TGTX) last released its earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.01). The company had revenue of $83.90 million for the quarter, compared to analysts’ expectations of $81.68 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The firm’s revenue for the quarter was down 49.4% on a year-over-year basis. During the same period in the prior year, the firm earned $0.73 EPS. As a group, equities analysts predict that TG Therapeutics will post 0.17 earnings per share for the current fiscal year.

Insider Transactions at TG Therapeutics

In other TG Therapeutics news, Director Sagar Lonial sold 5,000 shares of the stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $30.44, for a total transaction of $152,200.00. Following the sale, the director now directly owns 100,195 shares in the company, valued at $3,049,935.80. This represents a 4.75 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 10.50% of the company’s stock.

Institutional Investors Weigh In On TG Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. NBC Securities Inc. lifted its holdings in TG Therapeutics by 58.9% during the 3rd quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 485 shares in the last quarter. Ashton Thomas Private Wealth LLC acquired a new stake in TG Therapeutics during the 2nd quarter worth approximately $35,000. Blue Trust Inc. lifted its holdings in TG Therapeutics by 127.3% during the 3rd quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 849 shares in the last quarter. ORG Wealth Partners LLC acquired a new stake in TG Therapeutics during the 3rd quarter worth approximately $53,000. Finally, DekaBank Deutsche Girozentrale acquired a new stake in TG Therapeutics during the 1st quarter worth approximately $58,000. 58.58% of the stock is currently owned by institutional investors and hedge funds.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.